The impact of Hydroxyurea on the rates of Vaso–occlusive crises in patients with sickle cell disease in Saudi Arabia: a single–center study (original) (raw)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries

Jamlick Karumbi

Archives of Disease in Childhood, 2013

View PDFchevron_right

Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria

Lewis Hsu

American journal of hematology, 2018

View PDFchevron_right

Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease

H. Verma

View PDFchevron_right

Long-Term Outcomes in Patients with Sickle Cell Disease and Frequent Vaso-Occlusive Crises

syed hasan

The American Journal of the Medical Sciences, 2003

View PDFchevron_right

Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease

Renee Wilson

Annals of Internal Medicine, 2008

View PDFchevron_right

Preoperative Management of Sickle Cell Patients with Hydroxyurea

Aynur Ozbay

World Family Medicine Journal/Middle East Journal of Family Medicine, 2015

View PDFchevron_right

Hydroxyurea for the Treatment of Sickle Cell Disease

Arjumand S. Warsy

Acta Haematologica, 1992

View PDFchevron_right

Changes during vaso-occlusive crisis (VOC) and normal state in sickle cell disease patients

Joy Ikekpeazu

Medical Case reports and Reviews, 2019

View PDFchevron_right

Hydroxyurea Use Among Children With Sickle Cell Disease at King Abdulaziz University Hospital in Jeddah City

Fatima AlSinan

Cureus, 2021

View PDFchevron_right

Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent

Gian Forni

Blood cells, molecules & diseases, 2017

View PDFchevron_right

Hydroxyurea usage awareness among patients with sickle‐cell disease in Saudi Arabia

Abdul Sattar Khan

Health Science Reports, 2021

View PDFchevron_right

The use of hydroxyurea in sickle cell disease: A single tertiary centre experience at the National Hospital, Abuja, Nigeria

Oluseyi Oniyangi

South African Journal of Child Health, 2019

View PDFchevron_right

Acute events in hospitalized patients with sickle cell anemia before and after the use of hydroxyurea

Marcos Antonio Ferreira Júnior

International Archives of Medicine, 2016

View PDFchevron_right

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

James Eckman

American Journal of Hematology, 2010

View PDFchevron_right

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease

Julio Delgado

HemaSphere, 2021

View PDFchevron_right

The Efect of Hydroxyurea therapy on Adverse Clinical Events and Haematological Indices in Paediatric Patients with Sickle Cell Anaemia

Curt Bodkyn

West Indian Medical Journal, 2016

View PDFchevron_right

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)

Klio Sinopoulou

Blood, 2010

View PDFchevron_right

The Effect of Hydroxyurea Therapy in Bahraini Sickle Cell Disease Patients

ameera radhi

Indian Journal of Hematology and Blood Transfusion, 2015

View PDFchevron_right

The influence of hydroxyurea on oxidative stress in sickle cell anemia

Milton Ruiz

Revista Brasileira de Hematologia e Hemoterapia, 2012

View PDFchevron_right

Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia

Paul Visintainer

The Journal of Pediatrics, 1996

View PDFchevron_right

Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance

Ademola Adewoyin

African health sciences, 2017

View PDFchevron_right